Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
about
Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriersBRCAness: finding the Achilles heel in ovarian cancerGenetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapyPARP inhibitors in the management of breast cancer: current data and future prospectsBRCA1, a 'complex' protein involved in the maintenance of genomic stabilityGenomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancersGenome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer riskUpdate on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatmentExamining the Relationship between Pre-Malignant Breast Lesions, Carcinogenesis and Tumor Evolution in the Mammary Epithelium Using an Agent-Based ModelIntensified surveillance for early detection of breast cancer in high-risk patientsPersonalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998-2002.Realizing the promise of cancer predisposition genes.Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation CarriersBRCA1 deficiency exacerbates estrogen-induced DNA damage and genomic instabilityTriple-negative breast cancer in African-American women: disparities versus biology.Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer.Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors.BRCA-associated ovarian cancer: from molecular genetics to risk managementAGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2014.BRCA2 mutations and triple-negative breast cancerHereditary breast cancer: clinical, pathological and molecular characteristics.First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case reportEffect of tubal sterilization technique on risk of serous epithelial ovarian and primary peritoneal carcinomaRelationships between computer-extracted mammographic texture pattern features and BRCA1/2 mutation status: a cross-sectional studyClassifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling.Characterization of an Italian founder mutation in the RING-finger domain of BRCA1.Histologic features of melanoma associated with CDKN2A genotype.Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.Lobular breast cancer: incidence and genetic and non-genetic risk factors.Genotype/Phenotype correlations in patients with hereditary breast cancerAssociations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriersIdentification of six new susceptibility loci for invasive epithelial ovarian cancer.Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers.Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.BRCA 1/2 gene mutation and gastrointestinal stromal tumours: a potential associationRecurrent BRCA1 and BRCA2 mutations in Mexican women with breast cancerBreast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170.
P2860
Q24598482-C6B0550F-39DF-4F20-AF1C-94A57C0CFF3CQ24630872-76C48AB7-7106-43C7-9BEA-E486E176FC7DQ26769604-19719E7C-D7B9-4E70-B1C0-DE69CEA048B6Q26798352-4E03DCED-771C-424E-A532-F4DBEF52F527Q26853262-6A672066-0655-4507-AD70-9FAF95BA579EQ27006938-48FD24D4-22E3-4F75-BCCC-AF9667D32618Q27008356-F0B57B62-0315-4465-A724-83C3F6A92D64Q28075761-6BA07F9F-A616-4224-A14C-EB6482C3794FQ28390826-474C9C7F-5C84-411B-911C-593A37D7563CQ30392157-FAA292FC-F62F-4CE1-9F79-836FD7DF5656Q30543788-2F75B518-EC52-43F0-A792-C06030C39F14Q30692732-36DEE190-1D7F-467F-9F11-8F79272A7E35Q30743260-07834C36-1A7B-48E7-A971-0C6C58FCFF23Q31043651-C8F14DEA-41B7-4EF0-AEFB-0A46A2E829BCQ33614244-F3F8C92A-4F1E-43B1-9E52-7B5604D89200Q33624839-1BA682C9-E8D0-4D3B-A40D-DFBB008103A9Q33797203-6C5EFB08-4FDB-4D4B-B3EF-13F71527D1C0Q33915040-FF056FF4-9B27-4210-ACAA-D756B2294A2CQ33955266-DE8DA822-137B-4ED6-90EB-7E968B9E7761Q34032766-93C88645-6972-4555-9CE2-3221CB291EFCQ34042627-422ACB77-3CC6-4BF4-B851-550DDCBA39CDQ34293001-71AA8B4A-EDA3-464C-83EA-65BBD7B063F7Q34425230-42AF08FB-8F27-4CD3-9F86-45845F2650C3Q34572133-C31D6468-E7D4-4673-B191-B2B962420F34Q34714707-CF31ED40-3233-4DD5-9984-F37290E8DCD8Q34719906-F118F10E-F66C-4951-BC1A-89204CA85203Q34738030-22B714A3-05B9-4598-A55D-073064DDFAC9Q35091400-C541666D-0973-4B28-A621-FDE10D04A4A2Q35097007-973E1B0C-61BC-45AC-9546-34D59F4D26B0Q35155449-ABF82BC0-3A9F-48E2-930C-39530A0547B5Q35170028-09CB323F-44BB-4B52-B6EA-909FFF4C20E5Q35399541-436E3FBF-4614-4E6F-B713-495B93E70DA8Q35523236-665D202C-376E-4667-955D-7358262DB1A1Q35541663-831369CE-8982-47B1-AE35-F9390A9D864AQ35685370-27E75B6A-6AE0-48C9-8101-5F911E0AD3EAQ35690548-1D799B1C-56B2-43BA-B146-B76B0C7E245BQ35749439-3A741B08-3113-4BF2-B6A2-9666691A15FFQ35823594-CD892035-F6AD-47C0-8A25-08110868FE3DQ35830539-87CBFF12-C602-4876-AD3C-70DC1702EEFAQ35940158-C88268BE-7680-4BEE-AEFF-1925BBDD4AAC
P2860
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Pathology of breast and ovaria ...... f Modifiers of BRCA1/2 (CIMBA)
@ast
Pathology of breast and ovaria ...... f Modifiers of BRCA1/2 (CIMBA)
@en
type
label
Pathology of breast and ovaria ...... f Modifiers of BRCA1/2 (CIMBA)
@ast
Pathology of breast and ovaria ...... f Modifiers of BRCA1/2 (CIMBA)
@en
prefLabel
Pathology of breast and ovaria ...... f Modifiers of BRCA1/2 (CIMBA)
@ast
Pathology of breast and ovaria ...... f Modifiers of BRCA1/2 (CIMBA)
@en
P2093
P2860
P50
P1476
Pathology of breast and ovaria ...... f Modifiers of BRCA1/2 (CIMBA)
@en
P2093
Adalgeir Arason
Alexandra Stavropoulou
Andrew K Godwin
Anna von Wachenfeld
Barbara Pasini
Beth Karlan
Beth N Peshkin
Bjarni A Agnarsson
Carmen Cañadas
Carole Brewer
P2860
P304
P356
10.1158/1055-9965.EPI-11-0775
P50
P577
2011-12-05T00:00:00Z